AQS Insider Trading (Aequus Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$72,500.00
Insider Selling (Last 12 Months): C$0.00
Aequus Pharmaceuticals Share Price & Price History
Current Price: C$0.07
Price Change: ▲ Price Increase of +0.005 (7.69%)
As of 05/9/2022 06:42 PM ET
Warning: The Last Value Play Gone After August?
From Oxford Club | Ad
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Aequus Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/1/2021 | Doug Janzen | Director | Buy | 500,000 | C$0.15 | C$72,500.00 | 11,958,800 | |
| 4/27/2021 | Doug Janzen | Director | Buy | 41,000 | C$0.19 | C$7,585.00 | 10,999,800 | |
| 1/15/2021 | Doug Janzen | Director | Buy | 130,000 | C$0.12 | C$15,600.00 | 9,326,300 | |
| 12/31/2020 | Doug Janzen | Director | Buy | 100,000 | C$0.11 | C$11,000.00 | 9,196,300 | |
| 12/29/2020 | Doug Janzen | Director | Buy | 100,000 | C$0.10 | C$10,100.00 | 9,096,300 | |
| 10/30/2020 | Doug Janzen | Director | Buy | 21,500 | C$0.13 | C$2,687.50 | 8,646,300 | |
| 10/20/2020 | Doug Janzen | Director | Buy | 150,000 | C$0.10 | C$15,150.00 | 8,624,800 | |
Warning: The Last Value Play Gone After August?
From Oxford Club | Ad
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
SEC Filings (Institutional Ownership Changes) for Aequus Pharmaceuticals (CVE:AQS)
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Read More on Aequus Pharmaceuticals
Today's Range
Now: C$0.07
52 Week Range
Now: C$0.07
Volume
45,001 shs
Average Volume
51,765 shs
Market Capitalization
C$9.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Aequus Pharmaceuticals?
